Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers

International Journal of Antimicrobial Agents

Volumn 31, Issue 4, 2008, Pages 396-398

  Granizo, J J ^a   Sadaba B ^b   Honorato, J ^b   Gimenez, M J ^c   Sevillano, D ^c   Aguilar, L ^c   Coronel, P ^d  

^a Grana Datos SL   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Tedec Meiji Farma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFDITOREN PIVOXIL;

BACTERIOSTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; HUMAN; HUMAN EXPERIMENT; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMPUTER SIMULATION; ENDPOINT DETERMINATION; FASTING; HUMANS; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD; SERUM BACTERICIDAL TEST;

EID: 40849141127     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.10.024     Document Type: Letter

References (7)

1. Turnidge J., and Paterson D.L. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20 (2007) 391-408
2. Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother 2007 May 7 [Epub ahead of print].
3. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
4. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., Klugman K.P., Mabry L.R., Musher D.M., et al., Therapeutic Working Group. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae. Arch Intern Med 160 (2000) 1399-1408
5. Sadaba B., Azanza J.R., Quetglas E.G., Campanero M.A., Honorato J., Coronel P., et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter 20 (2007) 51-60
6. D'Argenio D.Z., and Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9 (1979) 115-134
7. Sevillano D., Giménez M.J., Alou L., Aguilar L., Cafini F., Torrico M., et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 60 (2007) 156-158